“Patients With Cardiovascular Risk Factors and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer)”. 2025. SKIN The Journal of Cutaneous Medicine 9 (6): s612. https://doi.org/10.25251/m9gw3y80.